Frontiers in Oncology:蘑菇有奇效!研究表明蘑菇提取物可清除HPV感染

2022-07-09 木子久 生物探索

根据美国德克萨斯大学休斯顿健康科学中心的一项研究,每天服用蘑菇提取物——活性己糖相关化合物可有效支持宿主免疫系统清除持续性HPV感染。

摘要目前,清除持续性高危HPV感染的有效选择较为有限,并且大多数涉及侵入性手术或局部治疗,尽管可以去除病变,但患者常常会出现复发性病变。因此,寻求有效清除HPV感染的治疗方式至关重要。

人乳头瘤病毒(Humaan papillomavirus,HPV)被归类为无包膜的双链DNA病毒,通常感染细胞的上皮层,包括皮肤和粘膜表面,并与良性疣、原位癌和恶性病变有关。在人类中发现了100多种HPV毒株,40种与生殖器疣相关的低危HPV(Low-risk HPV,LR-HPV)毒株,以及15种与癌症相关的高危HPV(High-risk HPV,HR-HPV)毒株。当HR-HPV感染持续存在时,感染者罹患癌症的风险增加。

虽然HPV疫苗接种在预防HPV感染方面是有效的,但对已经感染HPV的患者的治疗几乎没有益处。根除HR-HPV感染的有效治疗选择很少,通常是采用冷冻疗法、手术切除、环形电外科切除术或冷刀锥切术进行治疗,但是即使经过治疗,感染者还可能会出现复发性病变。用于LR-HPV的治疗方式包括局部应用鬼臼毒素或咪喹莫特,复发率分别为40%、15%。因而研究出有效清除HPV感染的药物或治疗方式很有必要。

根据美国德克萨斯大学休斯顿健康科学中心的一项最新研究,每天服用蘑菇提取物——活性己糖相关化合物(Active hexose correlated compound,AHCC)可有效支持宿主免疫系统清除持续性HPV感染,并且耐受性良好,未报告明显的不良副作用。这项研究结果以“AHCC?Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections”为题,发表在Frontiers in Oncology上。最终研究结果表明,在没有其他有效治疗选择的情况下,可以选择AHCC,清除持续性HPV感染。

图1 研究成果(图源:Frontiers in Oncology)

这是一项双盲、安慰剂对照的临床研究,研究人员共招募了50名患有高危HPV的女性,其中41人完成了研究。受试者被随机分配至治疗组和安慰剂组,治疗组的受试者首先接受了6个月的AHCC补充剂治疗,随后接受了6个月的安慰剂治疗,安慰剂组受试者则接受了为期12个月的口服安慰剂治疗。

试验的主要结果是评估持续性高危HPV感染的清除率。研究结果显示,AHCC补充剂治疗组22名受试者中有14名在治疗6个月后HPV转阴,治疗有效率达63.6%;相比之下,安慰剂治疗组19名受试者中仅有2名在治疗12个月后HPV转阴,治疗有效率仅为10.5%,远低于AHCC治疗。此外,有12名患者完成了非盲研究,在AHCC补充剂治疗6个月之后,6名患者HPV转阴,治疗有效率达50%。将34名接受AHCC补充剂治疗的患者数据总结分析,研究人员发现HPV感染总缓解率为58.8%。总体上来说,AHCC补充剂并没有明显的副作用,其毒性特征与安慰剂相当。

总之,这项研究结果表明,每天服用一次剂量为3g的AHCC补充剂,可有效支持宿主免疫系统消除持续性HPV感染,并且耐受性良好,未报告明显的不良副作用。

该项研究首席研究员、德克萨斯大学休斯顿分校麦戈文医学院妇产科和生殖科学系教授、药学博士Judith A. Smith表示:“我们的研究结果表明,AHCC非处方营养补充剂可以帮助大多数患者消除HPV感染,并可能降低HPV相关癌症的长期风险。”

虽然AHCC补充剂可能无法帮助所有持续性感染高危HPV的患者,但是在没有其他更有效治疗选择的情况下,AHCC补充剂是一种很好的选择,可有效清除持续性HPV感染。

题图来源:iStock,仅用于学术交流。

原始出处:

Smith JA, Gaikwad AA, Mathew L, et al. AHCC Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Front. Oncol. 12:881902. doi: 10.3389/fonc.2022.881902

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2169925, encodeId=6e5221699258b, content=国内有药吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a128684556, createdName=ms7000000670251980, createdTime=Tue Nov 21 12:16:59 CST 2023, time=2023-11-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1878555, encodeId=760118e855537, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 18 18:10:09 CST 2023, time=2023-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674510, encodeId=9a8216e4510a3, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 03 21:10:09 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866658, encodeId=20bd18666584c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 29 14:10:09 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483050, encodeId=89e01483050a0, content=<a href='/topic/show?id=0ac39080cc' target=_blank style='color:#2F92EE;'>#HPV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9080, encryptionId=0ac39080cc, topicName=HPV感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56437868203, createdName=ms3415360956839622, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570518, encodeId=122e15e051848, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=)]
    2023-11-21 ms7000000670251980 来自浙江省

    国内有药吗

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2169925, encodeId=6e5221699258b, content=国内有药吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a128684556, createdName=ms7000000670251980, createdTime=Tue Nov 21 12:16:59 CST 2023, time=2023-11-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1878555, encodeId=760118e855537, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 18 18:10:09 CST 2023, time=2023-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674510, encodeId=9a8216e4510a3, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 03 21:10:09 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866658, encodeId=20bd18666584c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 29 14:10:09 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483050, encodeId=89e01483050a0, content=<a href='/topic/show?id=0ac39080cc' target=_blank style='color:#2F92EE;'>#HPV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9080, encryptionId=0ac39080cc, topicName=HPV感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56437868203, createdName=ms3415360956839622, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570518, encodeId=122e15e051848, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=)]
    2023-04-18 anminleiryan
  3. [GetPortalCommentsPageByObjectIdResponse(id=2169925, encodeId=6e5221699258b, content=国内有药吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a128684556, createdName=ms7000000670251980, createdTime=Tue Nov 21 12:16:59 CST 2023, time=2023-11-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1878555, encodeId=760118e855537, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 18 18:10:09 CST 2023, time=2023-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674510, encodeId=9a8216e4510a3, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 03 21:10:09 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866658, encodeId=20bd18666584c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 29 14:10:09 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483050, encodeId=89e01483050a0, content=<a href='/topic/show?id=0ac39080cc' target=_blank style='color:#2F92EE;'>#HPV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9080, encryptionId=0ac39080cc, topicName=HPV感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56437868203, createdName=ms3415360956839622, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570518, encodeId=122e15e051848, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2169925, encodeId=6e5221699258b, content=国内有药吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a128684556, createdName=ms7000000670251980, createdTime=Tue Nov 21 12:16:59 CST 2023, time=2023-11-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1878555, encodeId=760118e855537, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 18 18:10:09 CST 2023, time=2023-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674510, encodeId=9a8216e4510a3, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 03 21:10:09 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866658, encodeId=20bd18666584c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 29 14:10:09 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483050, encodeId=89e01483050a0, content=<a href='/topic/show?id=0ac39080cc' target=_blank style='color:#2F92EE;'>#HPV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9080, encryptionId=0ac39080cc, topicName=HPV感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56437868203, createdName=ms3415360956839622, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570518, encodeId=122e15e051848, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=)]
    2023-01-29 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=2169925, encodeId=6e5221699258b, content=国内有药吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a128684556, createdName=ms7000000670251980, createdTime=Tue Nov 21 12:16:59 CST 2023, time=2023-11-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1878555, encodeId=760118e855537, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 18 18:10:09 CST 2023, time=2023-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674510, encodeId=9a8216e4510a3, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 03 21:10:09 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866658, encodeId=20bd18666584c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 29 14:10:09 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483050, encodeId=89e01483050a0, content=<a href='/topic/show?id=0ac39080cc' target=_blank style='color:#2F92EE;'>#HPV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9080, encryptionId=0ac39080cc, topicName=HPV感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56437868203, createdName=ms3415360956839622, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570518, encodeId=122e15e051848, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2169925, encodeId=6e5221699258b, content=国内有药吗, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a128684556, createdName=ms7000000670251980, createdTime=Tue Nov 21 12:16:59 CST 2023, time=2023-11-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1878555, encodeId=760118e855537, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Apr 18 18:10:09 CST 2023, time=2023-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674510, encodeId=9a8216e4510a3, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 03 21:10:09 CST 2022, time=2022-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866658, encodeId=20bd18666584c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Jan 29 14:10:09 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483050, encodeId=89e01483050a0, content=<a href='/topic/show?id=0ac39080cc' target=_blank style='color:#2F92EE;'>#HPV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9080, encryptionId=0ac39080cc, topicName=HPV感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=56437868203, createdName=ms3415360956839622, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570518, encodeId=122e15e051848, content=<a href='/topic/show?id=5f2288493b1' target=_blank style='color:#2F92EE;'>#蘑菇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88493, encryptionId=5f2288493b1, topicName=蘑菇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbb15667433, createdName=楚秀娟, createdTime=Sun Jul 10 11:10:09 CST 2022, time=2022-07-10, status=1, ipAttribution=)]
    2022-07-10 楚秀娟

相关资讯

Advances in Nutrition:大规模研究表明:多吃蘑菇与癌症风险降低有关,尤其是乳腺癌

近日,美国宾夕法尼亚州立大学的研究人员在 Advances in Nutrition 期刊发表了题为:Higher Mushroom Consumption Is Associated with Lo

《柳叶刀》:牛粪堆上的『致幻』蘑菇可能是抑郁症患者的大救星

据世界卫生组织估算,全球有至少3.5亿人受到抑郁症的折磨。他们长期受忧伤、自卑、失眠、厌食的困扰,他们在生活中找不到乐趣和意义。这种状态可能会伴随他们几十年,甚至是一辈子。幸而普通的抗抑郁药物和认知行为治疗对大部分人都有一定的作用,才部分地缓解了患者的痛苦。然而,有20%左右的患者对传统治疗手段表现出『抗性』,他们患的叫难治性抑郁症。这7000多万的患者只能在抑郁中艰难度日。我还记得上个月好像

Angew Chem Int Ed Engl:迷幻药被成功合成

一个研究小组在弗里德里希席勒大学耶拿已经找到如何制作赛洛西宾的方法,是导致食用天然蘑菇的人产生幻觉的化学物质。

国家卫生健康委特别提醒:餐桌上出现这些食物千万别吃!

今年以来,我国发生多起毒蘑菇和有毒动物、有毒植物中毒事件,截至5月上旬已报告造成261人中毒、6人死亡。为预防和控制毒蘑菇和有毒动植物中毒发生,保障人民群众健康与生命安全,特发布以下提示:

这种蘑菇,可以缓解癌症患者的“蓝瘦”

含有裸盖菇素的裸盖菇,被称为“神圣的蘑菇”或“幻觉蘑菇”癌症患者的“蓝瘦”2010年,Dinah Bazer被诊断患有卵巢癌。经过化疗等相应治疗手段后,症状有所缓解。不过随着时间的推移,她变得越来越担心癌症会复发。两年后,她的恐惧感比以往任何时候都更糟。她表示,恐惧正在吞噬着自己的生命,快要毁了她的生活。后来,Bazer听说纽约大学正在开展一项研究:医生使用裸盖菇素(一类具神经致幻作用的神经毒